Home/Filings/4/0000899243-20-012850
4//SEC Filing

ADELMAN DANIEL C MD 4

Accession 0000899243-20-012850

CIK 0001631650other

Filed

May 11, 8:00 PM ET

Accepted

May 12, 5:15 PM ET

Size

6.2 KB

Accession

0000899243-20-012850

Insider Transaction Report

Form 4
Period: 2020-05-10
ADELMAN DANIEL C MD
Chief Medical Officer
Transactions
  • Award

    Common Stock, $0.0001 par value

    2020-05-10+2,42029,715 total
Footnotes (4)
  • [F1]These shares represent restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest as to 100% of the underlying shares on September 11, 2020 (the "Vesting Date"), subject to the Reporting Person's continued service relationship with the Issuer on the Vesting Date.
  • [F2]Includes 8,750 RSUs and will be settled in common stock upon vesting. The RSUs vest in three successive, equal, annual installments measured from March 1, 2020, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.
  • [F3]Includes 8,906 RSUs and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from March 1, 2019, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.
  • [F4]Includes 7,031 RSUs and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from March 1, 2018, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.

Issuer

Aimmune Therapeutics, Inc.

CIK 0001631650

Entity typeother

Related Parties

1
  • filerCIK 0001222037

Filing Metadata

Form type
4
Filed
May 11, 8:00 PM ET
Accepted
May 12, 5:15 PM ET
Size
6.2 KB